• Теги
    • избранные теги
    • Компании1788
      • Показать ещё
      Разное566
      • Показать ещё
      Международные организации54
      • Показать ещё
      Страны / Регионы527
      • Показать ещё
      Издания58
      • Показать ещё
      Формат37
      Люди95
      • Показать ещё
      Показатели42
      • Показать ещё
17 января, 22:39

Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

16 января, 01:25

Trump Threatens BMW With Border Tax On Cars Built In Mexico

BERLIN, Jan 15 (Reuters) - President-elect Donald Trump has warned the United States will impose a border tax of 35 percent on cars that German carmaker BMW plans to build at a new plant in Mexico and export to the U.S. market. Trump was speaking in an interview with German newspaper Bild, which on Sunday released excerpts of his comments translated into German. A BMW spokeswoman said a BMW Group plant in San Luis Potosi would build the BMW 3 Series starting from 2019, with the output intended for the world market. The plant in Mexico would be an addition to existing 3 Series production facilities in Germany and China. Trump said BMW should build its new car factory in the United States because this would be “much better” for the company. He went on to say Germany was a great car producer, borne out by Mercedes Benz cars being a frequent sight in New York, but there was no reciprocity. Germans were not buying Chevrolets at the same rate, he said, making the business relationship an unfair one-way street. He said he was an advocate of free trade, but not at any cost. The BMW spokeswoman said the company was “very much at home in the U.S.,” employing directly and indirectly nearly 70,000 people in the country. (Reporting by Michael Nienaber and Edward Taylor; writing by Vera Eckert; editing by Andrew Roche) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

16 января, 01:25

Trump Threatens BMW With Border Tax On Cars Built In Mexico

FRANKFURT/BERLIN, Jan 16 (Reuters) - U.S President-elect Donald Trump warned German car companies he would impose a border tax of 35 percent on vehicles imported to the U.S. market, a plan that drew sharp rebukes from Berlin and hit the automakers’ shares. In an interview with German newspaper Bild, published on Monday, Trump criticized German carmakers such as BMW, Daimler and Volkswagen for failing to produce more cars on U.S. soil. “If you want to build cars in the world, then I wish you all the best. You can build cars for the United States, but for every car that comes to the USA, you will pay 35 percent tax,” Trump said in remarks translated into German. “I would tell BMW that if you are building a factory in Mexico and plan to sell cars to the USA, without a 35 percent tax, then you can forget that,” Trump said. Volkswagen (VW) shares closed down 2.2 percent, while BMW and Daimler’s shares ended 1.5 percent lower. Under pressure to deliver on campaign promises to revive U.S. industrial jobs, Trump has turned his fire on carmakers that use low-cost Mexican plants to serve the U.S. market. He has also warned Japan’s Toyota it could be subject to a “big border tax” if it builds its Corolla cars for the U.S. market at a planned factory in Mexico. All three German carmakers have invested heavily in Mexico, but also pointed out on Monday that they manufacturer in the United States as well. BMW executive Peter Schwarzenbauer told reporters the company was sticking to plans to invest around $1 billion in a new plant in Mexico, which is due to go into production in 2019 and create at least 1,500 jobs. SERIOUS WARNING “The president’s powers are considerable. He can legally impose tariffs of up to 15 percent for 150 days. Trump is not constrained by Congress,” said Simon Evenett, professor of international trade at Switzerland’s University of St Gallen. “Even if foreign companies object and seek to challenge the legality of tariffs, it will take at least 18 months to get decided. Corporate strategies will be disrupted by then.” While investing in Mexico, German carmakers have quadrupled light vehicle production in the United States over the past seven years to 850,000 units, more than half of which are exported from there, Germany’s VDA automotive industry association said. “In the long term, the United States would be shooting itself in the foot by imposing tariffs or other trade barriers,” VDA President Matthias Wissmann said in a statement. German carmakers employ about 33,000 workers in the United States and German automotive suppliers about 77,000 more, the VDA said. Speaking in tabloid newspaper Bild, German Economy Minister Sigmar Gabriel said that rather than trying to penalize German carmakers, the United States should instead respond by building better and more desirable cars. Norbert Roettgen, head of Germany’s foreign affairs committee, said Berlin needed to take Trump’s comments seriously. “He seems to be absolutely focused on short-term job interests and security interests ... not that he is looking for free trade so much, but more for protection,” he told Reuters. MEXICAN PLANS Daimler’s Mercedes-Benz and BMW already have sizeable factories in the United States where they build higher-margin sports utility vehicles (SUVs) for export to Asia and Europe. Around 65 percent of BMW’s production from its factory in Spartanburg, South Carolina, is exported overseas. BMW builds the X3, X4, X5 and X6 models in the United States. “It is surprising that Trump singles out the carmaker that exports more vehicles from the United States than any other manufacturer,” Evercore ISI analysts said. A BMW spokeswoman said the planned plant in the central Mexican city of San Luis Potosi would build the BMW 3 Series from 2019, with the output intended for the world market. The plant would be an addition to existing 3 Series production facilities in Germany and China. In June last year, BMW broke ground on the plant, pledging to invest $2.2 billion in Mexico by 2019 for annual production of 150,000 cars. Daimler has said it plans to begin assembling Mercedes-Benz vehicles in 2018 from a $1 billion facility shared with Renault-Nissan in Aguascalientes in Mexico. A spokesman for Daimler declined to comment on Trump’s remarks. Last year, VW’s Audi division inaugurated a $1.3 billion production facility with 150,000 vehicle production capacity near Puebla, Mexico. Audi said it would build electric and petrol Q5 SUVs in Mexico. Audi declined to comment on Monday. VW also declined to comment on Trump’s remarks but noted it was investing another $900 million in its U.S. plant in Chattanooga, Tennessee. Trump called Germany a great car producer, saying Mercedes-Benz cars were a frequent sight in New York, but claimed there was not enough reciprocity. Germans were not buying Chevrolets at the same rate, he said, calling the business relationship an unfair one-way street. Chevrolet sales have fallen sharply in Europe since parent company General Motors in 2013 said it would drop the Chevrolet brand in Europe by the end of 2015. Since then, GM has focused instead on promoting its Opel and Vauxhall marques. Asked by Reuters whether Trump could take any steps to make it easier for GM to sell more American-made cars in Europe, GM Chief Executive Mary Barra said the company aimed to build cars in markets where they are sold. “We’re a global company so we’re going to continue that focus just because from an economic perspective that generally turns out to be the best framework,” she said. “I think there is a lot that we can work on with President-elect Trump.” (Reporting by Edward Taylor, Ilona Wissenbach, Andreas Rinke, Andreas Cremer and David Shepardson; Editing by Keith Weir and Mark Potter) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
14 января, 23:26

Лалла Сальма и Моза.

Оригинал взят у cool_skarlet в Лалла Сальма и Моза.Какая курточка у короля! Это Мохаммеда и Лаллу Сальму застукали в неформальной обстановке.(Если это было - можно убрать).Лалла Сальма и Моза на Всемирном инновационном саммите по вопросам здоровья.Саммит, сразу видно, проходил в Дохе - так что Моза одета по всем правилам а жаль.Еще Лалла Сальма открыла центр раннего обнаружения рака шейки матки и груди.Еще, кажется, у нас не было фото с Riviera Awards 2016.Встреча с президентом Португалии.Посещение детского онкологического центра в Лиссабоне.На встрече с первой леди Сенегала.На подписании соглашения между ее фондом по борьбе с раком и Roche Laboratories относительно помощи малоимущим пациентам в получении инновационный лекарств.Заложение первого камня областного онкодиспансера.Открытие еще одного онкологического центра.Встреча с президентом ПортугалииПосещение детского онкологического центра в Лиссабоне.На встрече с первой леди Сенегала.На подписании соглашения между ее фондом по борьбе с раком и Roche Laboratories относительно помощи малоимущим пациентам в получении инновационный лекарств.Заложение первого камня областного онкодиспансера.Открытие еще одного онкологического центра.

13 января, 14:02

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

12 января, 16:22

Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.

Выбор редакции
10 января, 17:30

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche’s, Sanofi and Regeneron Pharmaceuticals

10 января, 17:12

Roche Gets Priority Review for Immunotherapy Drug Tecentriq

Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

Выбор редакции
09 января, 17:00

The FDA Approved Fewer Drugs in 2016: Here's Why

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

09 января, 16:49

LLabCorp: Reimbursement Scenario a Drag Amid Other Woes

On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.

07 января, 00:42

Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

Выбор редакции
03 января, 19:52

Why New Drug Approvals Are At A Six-Year Low In The U.S.

LONDON (Reuters) - Last year turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45. Across the Atlantic, the European Medicines Agency recommended 81 new prescription products against a 2015 total of 93. Unlike the FDA, the EMA includes generic drugs in its list. The slowdown suggests the pharmaceuticals industry may be returning to more normal productivity levels after a spike in approvals in 2014 and 2015, when the haul of new drugs reaching the market hit a 19-year high. Several factors led to the fall in the approval rate in 2016, John Jenkins, the FDA’s director of the office of new drugs, told a conference last month. Notably, five new drugs that had been scheduled for approval in 2016 ended up winning an early green light at the end of 2015. There was also a decline in drugs being filed for approval and the FDA rejected or delayed more applications in 2016 than in the previous two years. Some of the delayed drugs may yet go on to win approval in 2017, including Roche’s multiple sclerosis treatment Ocrevus and Sanofi and Regeneron’s sarilumab for rheumatoid arthritis. Most industry executives remain upbeat about the hunt for new medicines, given recent advances in fighting cancer and an improved understanding of the genetic basis of other diseases, which has resulted in full development pipelines at many firms. But it remains challenging to get new drugs through the approval process and to secure a decent financial return once they are launched, given resistance from healthcare insurers and governments to the rising cost of medical treatment. According to consultancy Deloitte, returns on research and development investment at the top 12 pharmaceutical companies fell to just 3.7 percent in 2016 from a high of 10.1 percent in 2010. Increasing political pressure over the high prices of many modern medicines is a growing challenge at a time when biotech and pharma companies are developing more drugs targeted at niche patient populations. The issue is exemplified by the last drug to win FDA approval in 2016. Spinraza, from Biogen and Ionis Pharmaceuticals, is the first medicine to treat patients with spinal muscular atrophy, a rare and often fatal genetic disease. It comes at a huge cost of $125,000 per dose. That price, implying a total cost of $625,000 to $750,000 for patients in the first year and $375,000 in subsequent years, is likely to invite “a storm of criticism, up to and including Presidential tweets”, according to Leerink analysts. President-elect Donald Trump has vowed to bring down drug prices.(Editing by Louise Heavens) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

30 декабря 2016, 16:40

AbbVie's Humira and Imbruvica Drive Performance in 2016

AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

Выбор редакции
30 декабря 2016, 10:11

Эффективный препарат от рака оказался смертельно опасным

Биотехнологическая компания Seattle Genetics сообщила, что четверо больных лейкемией, участвующих в клинических испытаниях нового противоракового препарата вадастуксимаба, умерли от нарушения функций печени. Изображение с сайта roche.com На заявление исследователей обратило внимание издание

29 декабря 2016, 16:03

LabCorp: Covance Drug Prospects Bright, Competition Rife

On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).

29 декабря 2016, 03:01

Breast cancer drug rejected for NHS use on cost-benefit grounds

Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine months on averageA breast cancer drug that costs £90,000 a year per patient has been turned down for use by the NHS on financial grounds, triggering an outcry from patients groups who say it prolongs the lives of people seriously ill with the disease.Kadcyla, made by Roche Pharmaceuticals, was rejected by the National Institute for Health and Care Excellence. It has the highest price tag ever for a cancer medicine and was turned down because its benefits did not justify its cost, Nice said. Continue reading...

Выбор редакции
29 декабря 2016, 01:26

Burkina Faso replaces army chief after series of attacks

OUAGADOUGOU (Reuters) - Burkina Faso President Roch Marc Christian Kabore replaced army chief of staff Pingrenoma Zagre on Wednesday, the government said in a statement, after a string of deadly militant attacks, including against the security forces.